Beth Seidenberg
Managing Director @ Westlake Village BioPartners
San Francisco, United States
Beth Seidenberg is a partner at Kleiner Perkins Caufield & Byers focused on life science investing. She works with entrepreneurs to develop companies with breakthrough technology for treating patients and improving health.Since joining KPCB in 2005, Beth has incubated five companies and serves on the board of directors of 3-V Biosciences,Armo Biosciences, Atara, Auxogyn, Breathe Technologies, Epizyme, iPierian, Redbrick Health and TESARO.Before joining KPCB, Beth was senior vice president of development and chief medical officer of Amgen, Inc.Earlier in her career, she was a senior executive in research and development at Bristol-Myers Squibb Co. and Merck & Co., Inc. Under her leadership, 10 innovative products were developed and marketed globally and achieved more than 40 regulatory approvals.Beth received her B.S. degree from Barnard College and her M.D. from the University of Miami. She completed her post-graduate training at Johns Hopkins University, George Washington University and the National Institutes of Health.
- Total investments:
- 35
- Last investment:
- Lead investor:
- 29%
Last updated:
For AI agents: llms.txt
Industries Beth Seidenberg invests in
Stages Beth Seidenberg invests in
Countries Beth Seidenberg invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 15 (43%)
- Health Care 13 (37%)
- Therapeutics 8 (23%)
- Medical 4 (11%)
- Biopharma 3 (9%)
Stage
- Series B 11 (31%)
- Series C 7 (20%)
- Series A 6 (17%)
- Series D 2 (6%)
- Funding Round 2 (6%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Oorja Bio
|
Oorja Bio is is a clinical-stage biotechnology company focused on developing therapies for idiopathic pulmonary fibrosis (IPF) and other fibrotic and cardiopulmonary diseases, with a focus on restoring lung tissue function and promoting cellular repair. | $30M / Series A / May 19, 2026 | |
Electra Therapeutics
|
Electra Therapeutics is a clinical stage biotechnology company developing therapies for cancer and other immunological diseases. | $183M / Series C / Oct 22, 2025 | |
Neuron23
|
Neuron23 is a developer of drugs intended to treat Parkinson's disease and Alzheimer's disease. | $96.5M / Series D / Jun 24, 2025 | |
Star Therapeutics
|
Star Therapeutics mission is to develop therapies for as many diseases as possible for millions of patients. | $90M / Series C / Sep 05, 2023 | |
Kyverna Therapeutics
|
KYVERNA is pioneering a new class of treatments and potential cures for serious autoimmune diseases. Their therapeutic platform combines advanced T cell engineering and synthetic biology technologies to suppress and eliminate the autoreactive immune cells at the root cause of inflammatory diseases. | $60M / Series B / Aug 03, 2023 | |
Kate Therapeutics
|
Kate Therapeutics is a patient-focused biotechnology company developing AAV-based gene therapies to treat genetically defined muscle and heart diseases. | $51M / Series A / Jun 08, 2023 | |
ACELYRIN
|
ACELYRIN is a biopharma company focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating the development and commercialization of promising drug candidates and by leveraging its expertise to rapidly advance these medicines to patients. | $300M / Series C / Sep 13, 2022 | |
ArsenalBio
|
ArsenalBio is building a programmable cell therapy company to create highly effective and accessible immune cell therapies to impact outcomes for a much broader number of patients, initially those with cancer. Founded in 2019, ArsenalBio is focused on integrating technologies such as CRISPR-based genome engineering, scaled and high throughputtarget identification, synthetic biology, and machine learning to advance a new paradigm to discover and develop immune cell therapies. With its programmable and computationally driven approach, ArsenalBio aspires to evolve critical metrics of success for immune cell therapies, including enhanced and broader efficacy, increased patient safety, reduced provider costs and expanded market access. | $220.8M / Series B / Sep 06, 2022 | |
|
Neuron23
|
Neuron23 is a developer of drugs intended to treat Parkinson's disease and Alzheimer's disease. | $100M / Series C / Mar 30, 2022 | |
|
Electra Therapeutics
|
Electra Therapeutics is a clinical stage biotechnology company developing therapies for cancer and other immunological diseases. | $84M / Series B / Feb 16, 2022 | |
| See all 35 investments → | |||
Co-Investors
Westlake Village BioPartners is a venture capital firm focused on incubating and building life sciences companies with entrepreneurs that have the potential to bring transformative therapies and technologies to patients. The Westlake model is built on the founding team’s unique experience in successfully identifying and developing breakthroughtherapies and building organizations.
Westlake Village BioPartners Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Sean E. Harper
Managing Partner
|
|||
|
Beth Seidenberg
Managing Director
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Beth Seidenberg invest in?
Beth Seidenberg invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series B and Series C stage. Most of the 35 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Beth Seidenberg?
Public channels for Beth Seidenberg include LinkedIn and X (Twitter). For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Beth Seidenberg last invest?
The most recent investment recorded for Beth Seidenberg closed in May 2026. Shizune tracks 35 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
